Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals ( ($TSE:FRX) ) has issued an announcement. On June 10, 2026, Fennec Pharmaceuticals Inc. held its annual meeting of sharehol...

Fennec Shareholders Approve Governance, Compensation and Equity Plans

An announcement from Fennec Pharmaceuticals ( ($TSE:FRX) ) is now available. On May 21, 2026, Fennec Pharmaceuticals announced that four independen...

Fennec Showcases New PEDMARK Data at ASCO 2026

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fennec Pharmaceuticals (FENC) and Sutro Biopharma (STRO). Fennec ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FENC	$9.06	+0.89%	372.70K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FENC	$9.06	+0.9%	372.70K
3
4
5
6

FENC

FENC

Get Fennec Pharmaceuticals Inc. Data in Excel

Get Fennec Pharmaceuticals Inc. Data in Excel